Safety of subcutaneous daratumumab in the treatment of plasma-cell disorders: A single-center experience. Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and ...

The rate of MGUS among hospitalized patients over 50 was twice as high as that of the same age group in the general population. Higher rates of MGUS were prevalent among patients who had elevated ...

Please provide your email address to receive an email when new articles are posted on . According to data from a population-based study, monoclonal gammopathy of undetermined significance was ...

Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is ...

Please provide your email address to receive an email when new articles are posted on . Patients with multiple myeloma who were previously diagnosed with monoclonal gammopathy of undetermined ...

GLP-1RA use was associate with lower risks for cardiovascular events among patients with monoclonal gammopathy of undetermined significance and type 2 diabetes. Use of glucagon-like peptide-1 receptor ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

Every year, scientists learn more about multiple myeloma, a type of blood cancer that starts in your bones. They’re working to figure out what causes this cancer and why some groups have a higher ...

If you have multiple myeloma, cancerous plasma cells divide and grow inside your bone marrow. Plasma cells are white blood cells that make antibodies. Antibodies are part of your immune system. They ...